Previous Close | 158.32 |
Open | 158.54 |
Bid | 153.46 x 0 |
Ask | 155.32 x 0 |
Day's Range | 154.36 - 158.54 |
52 Week Range | 119.00 - 168.52 |
Volume | |
Avg. Volume | 2 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Apr 26, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Key Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to their trading...
AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.